• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Strata Critical Medical Inc.

    11/4/25 5:07:38 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary
    Get the next $SRTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Strata Critical Medical, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    092667104

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    092667104


    1Names of Reporting Persons

    ARK Investment Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,404,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,404,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,404,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.52 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    092667104


    1Names of Reporting Persons

    Catherine D. Wood
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,404,585.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,404,585.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,404,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.52 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Strata Critical Medical, Inc.
    (b)Address of issuer's principal executive offices:

    31 Hudson Yards, 14th Floor New York, NY, 10001
    Item 2. 
    (a)Name of person filing:

    (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
    (b)Address or principal business office or, if none, residence:

    ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
    (c)Citizenship:

    (i) ARK: Delaware (ii) Catherine D. Wood: United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    092667104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    ARK and Catherine D. Wood: 6,404,585
    (b)Percent of class:

    ARK and Catherine D. Wood: 7.52
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) ARK: 6,404,585 (ii) Catherine D. Wood: 0

     (ii) Shared power to vote or to direct the vote:

    (i) ARK: 0 (ii) Catherine D. Wood: 6,404,585

     (iii) Sole power to dispose or to direct the disposition of:

    (i) ARK: 6,404,585 (ii) Catherine D. Wood: 0

     (iv) Shared power to dispose or to direct the disposition of:

    (i) ARK: 0 (ii) Catherine D. Wood: 6,404,585

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ARK Investment Management LLC
     
    Signature:/s/ Kellen Carter
    Name/Title:Kellen Carter, Chief Compliance Officer
    Date:11/04/2025
     
    Catherine D. Wood
     
    Signature:/s/ Catherine D. Wood
    Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
    Date:11/04/2025
    Get the next $SRTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Cohen Amir was granted 41,786 shares and covered exercise/tax liability with 20,497 shares, increasing direct ownership by 21% to 121,342 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    11/5/25 4:52:29 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Co-CEO and General Counsel Tomkiel Melissa M. was granted 208,929 shares and covered exercise/tax liability with 106,659 shares, increasing direct ownership by 8% to 1,372,642 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    11/5/25 4:52:21 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Co-CEO and CFO Heyburn William A. was granted 181,072 shares and covered exercise/tax liability with 100,133 shares, increasing direct ownership by 6% to 1,386,436 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    11/5/25 4:52:08 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Strata Critical Medical Announces Third Quarter 2025 Results

    Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1

    11/10/25 7:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces Date for Third Quarter Ending September 30, 2025 Earnings Release Conference Call

    NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b

    10/9/25 4:16:38 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Announces 2025 Investor Day

    NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), formerly known as Blade Air Mobility, Inc. (NASDAQ:BLDE), will hold an Investor Day at the Nasdaq MarketSite in New York City on Monday, November 17th 2025. The event will begin at 2:00pm ET and will include presentations by members of the management team. Investors and analysts can register for the Investor Day on the events section of Strata's Investor Relations website that can be found here. A live video webcast and presentation materials will be available on the day of the event at ir.stratacrtical.com. About Strata Critical Medical Strata is a time-critical

    9/30/25 4:00:00 PM ET
    $BLDE
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    SEC Filings

    View All

    SEC Form 10-Q filed by Strata Critical Medical Inc.

    10-Q - Strata Critical Medical, Inc. (0001779128) (Filer)

    11/10/25 11:51:14 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Strata Critical Medical, Inc. (0001779128) (Filer)

    11/10/25 7:06:04 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Strata Critical Medical Inc.

    SCHEDULE 13G/A - Strata Critical Medical, Inc. (0001779128) (Subject)

    11/4/25 5:07:38 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Financials

    Live finance-specific insights

    View All

    Strata Critical Medical Announces Third Quarter 2025 Results

    Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1

    11/10/25 7:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces Date for Third Quarter Ending September 30, 2025 Earnings Release Conference Call

    NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b

    10/9/25 4:16:38 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary